Market News & Trends
Agios Announces Publication of Phase 3 ACTIVATE-T Data Demonstrating Benefits of PYRUKYND for Adults With Pyruvate Kinase Deficiency
Agios Pharmaceuticals, Inc. recently announced data from the core period of the pivotal Phase 3 ACTIVATE-T study of PYRUKYND (mitapivat) in adults with pyruvate kinase (PK) deficiency who receive regular….
Kapruvia Approved in Switzerland With Additional Regulatory Decisions Expected in H2 2022
Cara Therapeutics, Inc. and Vifor Fresenius Medical Care Renal Pharma recently announced they have received approval for Kapruvia from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia will be the first….
Amydis Receives NIH Grant Award to Develop a Novel TDP-43 Retinal Tracer in Patients With ALS & FTD
Amydis Inc. recently announced a new Phase 1 grant award from the National Institute of Aging at the National Institutes of Health (NIH). The grant…
AUM Biosciences Receives FDA Orphan Drug Designation for the Treatment of Solid Tumors With the NTRK Fusion Gene
AUM Biosciences recently announced the US FDA has granted Orphan Drug Designation (ODD) to AUM601, a highly selective, oral small molecule that inhibits not only…
Gerresheimer & Zollner Enter Strategic Partnership
Gerresheimer AG and Zollner Elektronik AG are pooling their market-leading pharmaceutical and medical technology expertise under a strategic partnership. Starting immediately, they will offer pharmaceutical,…
Blue Water Vaccines Announces Exploration of its VLP Platform for Use in Monkeypox Vaccine Candidate
Blue Water Vaccines Inc. recently announced the company plans to explore the potential to develop a novel monkeypox vaccine using its norovirus shell and protrusion…
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Selective Allosteric TYK2 Inhibitor VTX958
Ventyx Biosciences, Inc. recently announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX958, a…
Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the US for Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function & Regeneration of Bowel Epithelium
Immunic, Inc. recently announced it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application 16/646130 titled Compound…
Artelo Biosciences Reports Positive Preclinical Results for Novel Inhibitor to Fatty Acid Binding Protein 5
Artelo Biosciences, Inc. recently announced publication of preclinical results indicating a novel fatty acid binding protein 5 (FABP5) inhibitor from the company’s FABP inhibitor platform…
Addex & Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders
Addex Therapeutics recently announced its collaboration agreement with Indivior PLC for discovering and developing novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM)…
Gerresheimer Invests Up to $94 Million in US Production Facility
Gerresheimer AG recently announced investments to rapidly expand its manufacturing, supply, and logistics capability for glass vials in the US. The project will be supported by the Biomedical Advanced Research….
Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE 81 mg
PLx Pharma Inc. is a commercial-stage drug delivery platform technology company focused on its clinically validated and patent-protected PLxGuard that has the potential to improve…
Kymanox Announces First Executive Advisor: Fran DeGrazio
Kymanox Corporation is honored to announce Fran DeGrazio to the newly formed Kymanox Executive Advisors team. This team of highly distinguished industry executives has led…
Priority Review Granted for the First Oral & First New SERD in 20 years to Treat Metastatic Breast Cancer
The Menarini Group and Stemline Therapeutics recently announced the US FDA has accepted the company’s New Drug Application (NDA) for elacestrant, an investigational selective estrogen…
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership With Ginkgo Bioworks
Synlogic, Inc. recently announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks The new candidate, SYNB2081, is a Synthetic…
Saama Collaborates With Merck to Build Machine Learning-Powered Clinical Data Layer to Strengthen Clinical Development Capabilities
Saama Technologies, LLC recently announced a multi-year agreement with Merck to build and operationalize a new clinical data layer leveraging Saama’s Life Science Analytics Cloud (LSAC) to….
Catalent to Acquire Metrics Contract Services for $475 Million
Catalent, Inc. recently announced it has reached an agreement to acquire Metrics Contract Services (Metrics), a full-service specialty Contract Development and Manufacturing Organization (CDMO) with a facility in….
VYNE Therapeutics Announces Results From Phase 2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
VYNE Therapeutics Inc. recently announced results from the Phase 2a segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic…
BD, Labcorp Collaborate to Develop Flow Cytometry-Based Companion Diagnostics for Matching Patients With Treatments
BD (Becton, Dickinson and Company) recently announced a collaboration agreement with Labcorp, a leading global life sciences company, creating a framework to develop, manufacture, market and commercialize….
Valneva & Pfizer Initiate Phase 3 Study of Lyme Disease Vaccine Candidate
Valneva SE and Pfizer recently announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and….
